Semaglutide Reduces All-Cause Death by 19% in SELECT Trial, Including Fewer COVID-19 Deaths

Semaglutide 2.4 mg vs placebo reduced all-cause death (HR 0.81, CI 0.71-0.93), non-CV death (HR 0.77, CI 0.62-0.95), and infectious death (HR 0.71, CI 0.51-0.98). Among COVID-19 patients, semaglutide reduced COVID deaths (HR 0.66, CI 0.44-0.96) and serious COVID events (232 vs 277, p=0.04). CV death trended lower (HR 0.85, CI 0.71-1.01).

Pre-specified analysis of the SELECT trial: double-blind RCT randomizing 17,604 participants ≥45 years, BMI ≥27, with established CV disease but without diabetes to semaglutide 2.4 mg weekly or placebo. Mean follow-up 3.3 years. All deaths adjudicated and categorized into CV, non-CV, and specific subcategories including COVID-19.

This is the first major trial to show a GLP-1 peptide drug reduces all-cause mortality in a large population. The unexpected finding of fewer infectious and COVID-19 deaths suggests semaglutide may have anti-inflammatory or immune-modulating effects beyond weight loss and cardiovascular protection.

This analysis transforms the narrative around semaglutide from a weight loss drug with CV benefits to potentially a life-saving medication with broad mortality reduction. The infectious death reduction raises provocative questions about whether GLP-1 peptides modulate immune function in clinically meaningful ways.

COVID-19 analysis is observational within an RCT — semaglutide didn't prevent COVID infection, only reduced severity. The CV death reduction didn't reach statistical significance (p=0.07). Death subcategory analyses have smaller numbers and should be considered exploratory. Trial excluded diabetic patients, limiting generalizability.